Novelix Pharma Q1 FY27 Results: Revenue Grows 65% to Rs 36 Crore, PAT Surges to Rs 1 Crore

Novelix Pharma Q1 FY27 results showed the pharmaceutical formulations company posting 65.15% revenue growth to Rs 36 crore from Rs 22 crore in Q1 FY26, reflecting new product launches, expanded distribution, or institutional pharma market entry.

The Novelix Pharma Q1 FY27 results showed gross profit jumping 625% from Rs 0.17 crore to Rs 1 crore on 65% revenue growth — a scale economy crossover where higher API procurement volumes and better capacity utilisation dramatically reduced per-unit manufacturing costs.

Click Here – Get Free Investment Predictions

Novelix Pharma Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Crore)	Q1 FY26 (Rs Crore)	YoY Change
Revenue	36.00	22.00	+65.15%
Gross Profit	1.00	0.17	+625.8%
Net Profit / PAT	1.00	0.11	+1001.78%

Novelix Pharma Q1 FY27 Performance Analysis

Use the Univest Screener to track Novelix Pharma live financials and Q1 FY27 results

Novelix Pharma Q1 FY27 results demonstrate pharmaceutical operating leverage. Revenue crossing a scale threshold reduces per-unit API and manufacturing costs, driving the disproportionate 625% gross profit improvement on 65% revenue growth.

PAT surging 1002% from Rs 0.11 crore to Rs 1 crore confirms the company is now meaningfully above its profitability breakeven point in pharmaceutical manufacturing.

At Rs 36 crore quarterly revenue and Rs 1 crore PAT (2.8% margin), Novelix Pharma has significant headroom for margin improvement as revenue scales further — pharma manufacturing margins typically improve substantially at higher volumes.

India's growing generic pharmaceutical market and government healthcare spending expansion provide structural demand tailwinds for formulations companies like Novelix Pharma.

Key Business Factors in Q1 FY27

Pharmaceutical Scale Economies

Higher API procurement volumes and better capacity utilisation drove the 625% gross profit improvement on 65% revenue.

Generic Pharma Growth

India's domestic and export generic pharma demand drives Novelix Pharma's revenue growth trajectory.

Operating Leverage

PAT surging 1002% on 65% revenue growth reflects pharmaceutical operating leverage above the breakeven threshold.

Dividend Details

Novelix Pharma has not declared a dividend for Q1 FY27. The company is reinvesting in product development and distribution expansion.

FY27 Outlook

The FY27 outlook is positive. Continued revenue growth with improving pharmaceutical manufacturing margins would significantly increase PAT from the Q1 FY27 results base.

Regulatory approvals, API cost management, and competition from larger pharma companies are the key risk factors.

Novelix Pharma Stock Performance

Download the Univest iOS App or Univest Android App to track Novelix Pharma share price live and stay updated on quarterly results.

Novelix Pharma shares traded at Rs 73.97 on August 13, 2026, up 1.34%, reflecting positive market reception of the Q1 FY27 results growth trajectory.

Key Risks

Regulatory Risk

New product launches require regulatory approvals. Delays would slow revenue growth.

API Price Volatility

Active pharmaceutical ingredient costs are subject to global supply fluctuations from key sourcing markets.

Competition from Larger Pharma

Generic formulations markets are competitive. Larger companies have scale and distribution advantages.

Conclusion

Novelix Pharma Q1 FY27 results show impressive 65% revenue growth to Rs 36 crore and PAT surging 1002% to Rs 1 crore as pharmaceutical scale economies kicked in.

Strong growth trajectory but investors should assess product pipeline and competitive positioning. Consult a SEBI-registered advisor.

Frequently Asked Questions on Novelix Pharma Q1 FY27 Results

When were Novelix Pharma Q1 FY27 results announced?

Ans. August 13, 2026, standalone basis.

What was Novelix Pharma revenue in Q1 FY27?

Ans. Rs 36 crore, up 65.15% from Rs 22 crore.

What was Novelix Pharma PAT in Q1 FY27?

Ans. Rs 1 crore, up approximately 1002% from Rs 0.11 crore.

Why did PAT surge 1002% on 65% revenue growth?

Ans. Scale economies in pharmaceutical manufacturing dramatically reduce per-unit API and production costs at higher volumes, crossing the profitability breakeven threshold.

Did Novelix Pharma declare a dividend?

Ans. No dividend for Q1 FY27.

What is the outlook?

Ans. Positive with continued revenue growth. Monitor regulatory pipeline and competition.

Is Novelix Pharma a good investment?

Ans. Strong growth story. Assess product portfolio and regulatory status. Consult a SEBI-registered advisor.